Icon Cancer Centre, Omico Partner to Expand Access to Precision Oncology for Australians

Icon Cancer Centre and Omico have announced an important collaboration aimed at expanding access to precision oncology and clinical trials for Australian cancer patients. By leveraging Icon’s extensive national network of cancer centres and Omico’s expertise in molecular profiling and targeted therapy trials, this partnership is set to improve access to cancer screening and evolve Australia’s cancer care landscape.

Increasing access to genomic profiling and research

This partnership will advance cancer care by making precision oncology more accessible in routine practice. It aims to provide Australians living with challenging cancers access to free comprehensive genomic profiling (CGP), opening the door to life-extending, personalised treatments that may otherwise remain unexplored.

The collaboration will also focus on expanding clinical trial availability across Icon’s national network, ensuring that more patients, including those in non-metropolitan and regional areas, can access advanced therapies and contribute to leading-edge research. It will also improve clinician engagement and support for integrating genomic-guided treatment options into everyday care.

The partnership focuses on Omico’s:

• PrOSPeCT (Precision Oncology Screening Program Enabling Clinical Trials), Australia’s largest precision oncology initiative. Through PrOSPeCT, 23,000 patients with advanced, incurable or poor prognosis cancers will receive free comprehensive genomic profiling (CGP) to identify potential matches with clinical trials, offering patients access to cutting-edge, personalised treatments.
• CaSP – The Cancer Screening Program within PrOSPeCT, receives patient referrals, coordinates CGP testing, and delivers a comprehensive report to the referring clinician – including genomic results and potential matches to molecularly guided trials, helping clinicians provide tailored treatment options for their patients.

Evolving targeted treatments

Icon Cancer Centre (ANZ) Director of Medical Oncology, A/Prof Louise Nott is looking forward to clinical improvements.

“Every cancer diagnosis is different, and genomic testing is transforming the way we treat cancer and deliver truly personalised care,” said A/Prof Nott.

“By identifying the unique drivers of a patient’s cancer, we can match them with targeted therapies and clinical trials that can offer improved outcomes. Partnering with Omico is a crucial step in evolving clinician access to genomic-guided treatment and ultimately ensuring patients have better access to innovative treatments.”

“Omico and Icon are united by a shared commitment: ensuring that access to precision oncology and clinical trials is not limited by geography,” said Ian.

“Together, we’re focused on building capacity beyond metropolitan centres so that people in regional and rural communities have the same opportunities for cutting-edge cancer care as those in our cities – equity of access must be the standard for every Australian affected by cancer.”

Meeting unmet needs in cancer care

Icon Cancer Centre CEO, Paul Fenton said this is another example of Icon’s commitment to partnerships in addressing care gaps.

“This partnership addresses a critical gap in patient access to precision oncology,” said Paul.

“This marks Omico’s first partnership with a national private cancer care provider, creating a new model for integrating precision oncology trials within community-based cancer care and supporting our mission to deliver the best care possible as close to homes as possible.”

Future healthcare

With more Icon centres actively participating in Omico-supported trials, the collaboration will strengthen biomarker-led research and contribute valuable real-world data on precision oncology. Ultimately, this initiative lays the foundation for a scalable, sustainable model that integrates precision medicine into routine cancer care, shaping the future of oncology in Australia.